11 Jan 2019 Research
Lymphoma: Understanding relapse and treatment resistance
What is this research looking at?
Our immune system is remarkable. It is made up of many different types of immune cells that work together to protect the body from infection by pathogens such as bacteria, viruses and parasites.
We are investigating what happens when a certain type of cell in the immune system, known as B cells, starts growing out of control and develops into blood cancers such as leukaemia, lymphoma and myeloma.
We want to know what happens when B cells mature normally from precursor cells in the bone marrow and discover what has gone wrong when they turn into cancer cells instead.
Considerable success has been achieved in the treatment of lymphoma. However, a significant unmet need remains: roughly 40% of patients either do not respond to treatment or the condition recurs after treatment. Currently, our ability to predict which patients will fail treatment is poor.
By taking a detailed look at B cells as they develop and specialise, we can spot small groups of dangerous cells that are particularly likely to turn into cancer and identify the genetic faults that drive B cells to grow out of control.
We are using our knowledge to create new models for the development of B cells and blood cancers in the lab, so we can find new ways to treat or even prevent these deadly diseases.
Our research uses a model of lymphoma to test the response to treatments and development of resistance. A main advantage of the model is that we can interrogate these questions on a well-defined scenario and can perform iterative tests and predictions. Further, the model generated in this project will allow initial testing of novel treatments.
What could this mean for people with leukaemia?
This research could inform the medical decision of when to use combination and novel therapies for patients with a higher probability of developing resistance to standard treatment, alongside bringing safer treatments to patients.
Official project title: Development of a model system to study diffuse large B cell lymphoma clonal evolution
Related posts
24 August 2022
Non-existent awareness of leukaemia symptoms “extremely worrying” – say leading UK leukaemia charities, as they launch memorable new campaign to get people “parroting on” about the symptoms
People over 55 also underestimate their risk, thinking that leukaemia is a childhood disease. Only 11% of over 55s thought that they had the greatest risk of leukaemia[1], whereas in…
2 August 2023
Friends and family of Leicestershire woman who died from rare cancer campaign for more research and awareness
The family of a Leicestershire woman who died in July 2022, on the day of her leukaemia diagnosis, has raised over £17,000 in her memory to support Leukaemia UK. On…
26 October 2021
Leukaemia UK announced as one of five charities for star-studded event Shall We Dance? with Dame Arlene Phillips and Anton Du Beke
Leukaemia UK is delighted to have been announced as one of five charities for whom the proceeds of a new star-studded dance event, Shall We Dance?, will go towards when it takes place next year.
15 February 2024
Vogue model who survived leukaemia as a child joins Leukaemia UK in calling for more donations for research to stop blood cancer ‘destroying childhoods’
Vogue model Saffron Vadher has joined Leukaemia UK on International Childhood Cancer Day (February 15th) in calling for more research into the blood cancer. Leukaemia is the most common type…